Biochemical modification of tissue-type plasminogen activator (t-PA) designed to alter pharmacokinetics and pharmacodynamics offers promise for development of pharmaceuticals particularly suitable for treatment of specific disorders and for induction of coronary thrombolysis by intramuscular as well as intravenous administration. Accordingly, to identify biochemical determinants of clearance of t-PA from the circulation, we injected rabbits intravenously with three different preparations of t-PA synthesized from the same human gene and expressed in Chinese hamster ovary cells cultured under disparate conditions. Influences of glycosylation on clearance were defined by experiments with enzymatically treated t-PA in which clearance was assessed with concomitant administration of selected neoglycoproteins that compete with t-PA for specific glycoprotein receptors. The role of an intact active catalytic site, as reflected by differences in clearance with and without prior treatment of t-PA with the protease inhibitor PPACK, was defined also. Results indicate that clearance is altered by inhibition of the active site and that the nature and extent of glycosylationnot evident simply by analysis of peptide structureinfluence clearance as well. These findings suggest that mannose/N-acetylglucosamine-specific glycoprotein receptors expressed on hepatic reticuloendothelial cells participate in clearance of t-PA from the circulation but that galactose-specific glycoprotein receptors probably do not. The observations may explain differences in clearance seen with different preparations of t-PA that have been seen in clinical pilot studies and may identify biochemical determinants of clearance amenable to modification for development of agents with potentially desirable, specific biological properties. Circulation 77, No. 4, 906-914, 1988. TISSUE-TYPE plasminogen activator (t-PA) produced by recombinant DNA technology (rt-PA) is a clinically promising thrombolytic agent for induction of coronary thrombolysis.i Its relative clot selectivity, efficacy, short half-life in the circulation facilitating prompt restoration of hemostatic integrity before emergency procedures, and lack of immunogenicity2-4 underlie enthusiasm for its use.
nants of clearance of t-PA from the circulation. Three preparations of human rt-PA, each of which was expressed in Chinese hamster ovary (CHO) cells, were characterized. Each preparation was obtained from media from cells cultured under different conditions. Results indicate that the three preparations were cleared differentially and that clearance was influenced both by glycosylation and by an intact active site. Biochemical differences attributable to diversity of complex-type oligosaccharides between preparations may explain these differences and those that have been observed previously. Mannose/N-acetylglucosamine-specific glycoprotein receptors (Man/GlcNAc receptors) expressed on hepatic reticuloendothelial cells appear to mediate clearance of rt-PA from the circulation.
Materials and methods
Three preparations of human rt-PA expressed from the same human cDNA in CHO cells (designated t-PA preparations I, II, and III) were obtained from Genentech, Inc., South San Francisco. Each was produced under specific and distinctive conditions employed at different times during the development of material for preclinical investigation. Preparation I was produced in large scale in suspension cell culture under manufacturing mode conditions. Preparation II was produced in suspension cell culture under pilot, small-scale conditions. Preparation III was produced in roller bottle cell culture.
Lyophilized material from each preparation was reconstituted with distilled water. Dilutions for injections in experimental animals were made with 0.2M arginine-phosphate buffer, pH 7.2 (excipient buffer), with solutions passed through sterile 0.22 ,um filters.
Bovine serum albumin (BSA), aprotinin, D-( + )-mannose, para-aminophenyl-ox-D-mannopyranoside-BSA and para-aminophenyl-N-acetyl-,-D-glucosaminide-BSA (BSA-Man and BSA-GlcNAc) (20 to 30 moles of monosaccharide per mole of BSA), chloramine-T, aL-mannosidase from jack beans, bovine thrombin, asialofetuin (ASF), Triton X-100, Tween-80, and conventional laboratory reagent-grade chemicals were obtained from Sigma Chemical Co., St. Louis. Human plasmin, human fibrinogen, and human plasminogen were purchased from Kabi Vitrum through Helena Laboratories, Beaumont, TX. Determination by enzyme-linked immunosorbent assay (ELISA) of t-PA antigen concentration was performed with Imubind kits from American Diagnostica, Greenwich, CT. The International Reference Preparation of t-PA (83/517) was obtained from Dr. P. J. Gaffney, National Institute for Biological Standards and Control, London, United Kingdom. Isoelectric points were determined with a Phast System from Pharmacia, Piscataway, NJ. Sephadex G-10, Sephadex G-50 fine, and concanavalin-A-Sepharose 4B (Con-A-Sepharose) were obtained from Pharmacia. D-Phenylalanyl-propyl-arginyl-chloromethyl ketone (PPACKI) was purchased from Calbiochem, San Diego. Carrier free Na' 15 (100 mCi/ml) was obtained from Amersham, Arlington Heights, IL. 'C-CMP-sialic acid (CMP-[14C]-NeuAc) was purchased from New England Nuclear, Boston. Protean II Minigel system, Poly-Prep columns, and sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) molecular weight standards were acquired from Bio Rad, Richmond, CA. Gal-3-(1,4)-GlcNAc-oa-(2,6)-sialytransferase, and endoglycosidase-H (Endo-H) were purchased from Genzyme Corp., Bos-ton. Vacutainer tubes (2.7 ml) containing trisodium citrate in a final concentration of 13 mM were purchased from Becton-Dickinson, Rutherford, NJ. New Zealand White rabbits weighing 2.0 to 3.0 kg were supplied by the M and K Co., St. Louis. Care and use of experimental animals conformed to the standards established by the Washington University Humane Care of Laboratory Animals Committee consistent with the Helsinki declaration.
Clearance of t-PA in vivo. Clearance of t-PA from the circulation was determined in rabbits anesthetized with xylazine (18 mg/kg im) and ketamine (60 mg/kg im). Rabbits were monitored physiologically throughout each experiment and were hemodynamically stable. Bolus injections of t-PA (0.2 mg/kg) were administered via a femoral venous catheter. Samples of whole blood were collected from a femoral arterial catheter with a two-syringe technique, transferred immediately into Vacutainer tubes containing sodium citrate at zero time and at 1, 2, 4, 6, 8, 10, 15, 30, 45 , and 60 min after administration of t-PA, and maintained at 00 to 40 C. Catheters were flushed with 2 ml of sterile saline after injection of t-PA and after acquisition of each sample.
Samples were centrifuged at lOQOg at 40 C for 10 min within 20 min after acquisition of the last sample. Aliquots of citrated plasma were frozen and stored at -700 C. Samples were thawed rapidly in a 370 C water bath and kept on ice before assay of t-PA antigen concentration in plasma with an ELISA as previously described.'4' 15 The clearance curves were consistently biexponential as judged by inspection.
Competitive inhibition of clearance. To determine the extent to which glycosylation of t-PA influenced clearance from the circulation, axand ,-phase half-lives of intravenously administered t-PA were determined with or without concomitant intravenous administration of two neoglycoproteins or ASF, each with a terminal monosaccharide moiety specific for the Man/GlcNAcor galactose-specific glycoprotein receptor. For this purpose BSA-Man, BSA-GlcNAc, and ASF were dialyzed against 10mM sodium phosphate buffer, pH 7.4, containing 150 mM NaCl and 0.01% (v/v) Tween-80 (PBS-Tween) and filtered through a 0.22 ,um filter before infusion. Intravenous bolus injections of receptor-specific glycoprotein (10 mg/kg) were administered 2 min before bolus injection of t-PA I or t-PA III (0.2 mg/kg). In separate experiments, BSA-Man and ASF (both 10 mg/kg) were administered simultaneously followed by t-PA 1 (0.2 mg/kg) 2 min later to determine whether competition for glycoprotein receptors affected clearance in an additive fashion.
Control experiments were performed with intravenous injections of D-( + )-mannose (0.76 mg/kg) or BSA (10 mg/kg) in molar amounts identical to those of each in the administered BSA-Man (20 to 30 moles mannose/mole BSA) before bolus injection of t-PA I (0.2 mg/kg).
a-Mannosidase treatment of t-PA. To determine whether selective deglycosylation oft-PA modified clearance, t-PAI (0.8 mg/ml) was exposed to 20 U of (x-mannosidase in 100 mM Tris-HCl, pH 7.4, containing 150 mM NaCI and 0.01% (vlv) Tween-80 (TBS-Tween) for 3 hr at 250 C. Separation of t-PA resistant to or incompletely demannosylated by (x-mannosidase was accomplished by affinity chromatography on Con-A-Sepharose.The reaction mixture (1 ml) was loaded onto a Poly-Prep column containing 1 ml Con-A-Sepharose equilibrated and eluted with TBS-Tween. Twenty percent of the t-PA treated with a-mannosidase did not bind to Con-A-Sepharose and was recovered in the eluted volume (13 ml) . Less than 0.2% of t-PA treated identically in the absence of a-mannosidase could be recovered after elution with the same volume of buffer, indicating that t-PA recovered after exposure to ax-mannosidase and Con-A-Sepharose chromatography comprised material free of exposed oligosaccharide terminal mannose residues available Vol. 77, No. 4, April 1988
for lectin binding. The integrity of the primary structure of t-PA after treatment with ax-mannosidase was confirmed by SDS-PAGE under reducing and nonreducing conditions. In control experiments, t-PA Iwas incubated at 250 C for 3 hr in TBS-Tween in the absence of enzyme. Half-life in the circulation was determined after injection of identical volumes and concentrations of demannosylated compared with control t-PA. Similar experiments were performed with Endo-H. Preparation of asialo-derivatives of t-PA. Asialo-derivatives of t-PA preparations I, II, and III were prepared for use as substrates in the sialyltransferase assay by mild acid hydrolysis. 6 Solutions of approximately 10 mg/ml of t-PA were titrated to pH 2.0 with concentrated HCl and incubated for 1 hr at 800 C. Liberated sialic acid was removed from asialo-t-PA by dialysis at 250 C against excipient buffer with 0.01% Tween-80. The integrity of asialo-derivatives was documented by SDS-PAGE under reducing conditions. Concentrations of t-PA before and after hydrolysis were monitored by assay of total protein. '7 Sialyltransferase assay. Sialylation of asialo-t-PA derivatives with CMP-['4C] NeuAc was performed with the Gal-(-(1,4)-GlcNAc-at-(2,6)-sialyltransferase (Genzyme Corp.) according to the method of Paulson and Hill. 16 The following components were incubated in a final volume of 50 ,l of t-PA excipient with 10mM sodium cacodylate, 0.01% Tween-80, and 0.2% triton CF-54, pH 6.0: CMP-[`4C] NeuAc (10 nmol, approximately 25,000 DPM/assay), BSA (50 Kzg), asialo-t-PA (25 to 100 ,ug), and ox-(2,6)-sialyltransferase (0.85 mU). Reactions were performed at 250 C for 8 hr, after which time maximal incorporation of CMP-[14C] NeuAc had occurred as determined by results of kinetic studies. Reactions mixtures were snap frozen at -800 C. Unincorporated label was removed from samples by gel filtration over a 0.7 x 30cm Sephadex G-50 fine column eluted with excipient buffer. Radioactivity in 0.5 ml fractions was assayed in Aquasol with a Beckman LS3801 scintillation counter. In the absence of sialyltransferase, only background radioactivity was detectable in the fractions containing t-PA, indicating adequate separation and lack of nonspecific binding of label to t-PA.
Conversion of singleto two-chain t-PA. To determine whether the proportion of single-chain to two-chain t-PA influenced circulating half-life, t-PA I, shown to be predominantly single chain, was converted entirely to its two-chain form by treatment of solutions of 2.5 mg/ml with plasmin, 0.03 casein units/mi, in PBS-Tween at 370 C for 1 hr. Plasmin activity was then inhibited by addition of aprotinin (200 kallikrein IU/mi). Completion of cleavage by plasmin and integrity of the primary structure of the two-chain t-PA formed was documented by SDS-PAGE under reducing conditions. For control experiments, t-PA was incubated at 370 C for 1 hr in the absence of plasmin followed by addition of aprotinin.
Activity of t-PA. Fibrinolytic activity was assessed by fibrin plate assay as previously described.'5'`8 The International Reference Preparations of t-PA was used as the reference standard for activity. Specific functional activity was expressed as fibrin plate activity (IU) per mass of antigen (ng) determined by ELISA.
lodination and inactivation of t-PA. t-PA I (200 Kug) in PBS-Tween was iodinated with carrier free Na 1251 (0.2 mCi) or an equivalent amount of unlabeled Nal (12 ng) by the chloramine-T method.`' Unincorporated iodine was removed by gel filtration over Sephadex-G-10 in Poly-Prep columns equilibrated and eluted with PBS-Tween. Radiolabeled t-PA I had a specific radioactivity of 2 x 106 CPM/,ug and was more than 95% precipitable with 10% (w/v) trichloroacetic acid. Fibrin plate specific activity and SDS-PAGE migration of iodinated t-PA were identical to corresponding results seen with untreated t-PA. Preparation 1 (0.2 mg/ml) was treated with PPACK at a final concentration of 2 ,uM for 1 hr at room temperature to delineate the influence of the serine protease catalytic site on clearance of t-PA in vivo.
Fibrin autography. The circulating forms of t-PA in plasma in samples obtained during the course of evaluation of clearance in vivo were characterized at selected intervals after administration of t-PA by fibrin autography with SDS-PAGE (4.0% stacking and 7.5% separating gels) as previously described.15
Polyacrylamide gels were washed in 2.5% triton X-100 for 60 min and placed on 8 x 6 cm fibrin indicator gels comprising 10 mM sodium phosphate and 150mM sodium chloride, pH7.4; 1.3% agar; 2.4 mg/ml fibrinogen; 0.2 NIH unit/ml thrombin; and 20 ,ug/ml plasminogen. Autographs were incubated at 370 C in a humidified environment and photographed serially with a Polaroid camera. The primary structures of the three preparations of t-PA used in this study were identical in view of their synthesis from the same gene expressed in the same cell line and judging from results of SDS-PAGE. Single chain forms of all three preparations exhibited a relative molecular weight of approximately 64 kilodaltons on SDS-PAGE gels under reducing conditions (figure 1). The ratio of the singleto the two-chain form in preparations I and II was approximately 2:1. Preparation III was composed of approximately equal amounts of singleand two-chain forms. The specific activities of preparations I, II, and III were 0.52 + 0.08 (n = 7), 0.58 ± 0.09 (n = 2), and 0.52 + 0.05 (n = 3) IU/ng, respectively (p = NS).
Isoelectric focusing of preparations I and II yielded four bands with identical isoelectric points (pls) of 5.4, 5.5, 5.8, and 6.2. The pIs of the predominant bands were 5.4 and 5.5. In contrast, preparation III exhibited three bands, distinct from those of preparation I and II with pls of 5.7, 5.9, and 6.5. The pIs of the predom- lives of the three preparations exhibited consistent differences. Table 1 represents pharmacokinetic data for each preparation. The plasma half-lives attributable exclusively to the a-phase averaged 0.82 0.15 min for preparation III in contrast to 1.16 ± 0.28 and 1.32 ± 0.32 min for preparations I and II. The plasma half-lives of the 1-phase of clearance for preparation II was 13.51 ± 3.05 min in contrast to 10.54 ± 2.28 and 8.89 ± 0.70 min for preparations I and III. Apparent volume of the central compartment was not statistically different among preparations.
The influence of glycosylation on clearance on t-PA. The influence of galactose-and Man/GlcNAc-specific glycoprotein receptors on clearance was evaluated by competition experiments in which ASF or neoglycoproteins of BSA conjugated with mannose or N-acetylgluco-samine were administered intraventously 2 min before injection of t-PA. These experiments were performed with two preparations of t-PA (I and III). As shown in table 2 and figure 4, a 50-fold molar excess of BSA-Man prolonged the half-time of ax-and of 3-phase clearance of preparation I substantially, as did BSA-GIcNAc, suggesting that the Man/GlcNAc-specific glycoprotein receptor contributes to the clearance of t-PA from the circulation. Competition with BSA-Man did not change the apparent volume of the central compartment. In contrast, a similar molar excess of ASF, a concentration sufficient to saturate the receptor judging from results with labeled and unlabeled ASF, exerted no influence on either the ox-phase or 13-phase clearance rate constant of preparation I (data not shown). BSA alone and D-(+ )-mannose alone in the same molar concentrations as present in BSA-Man used in competition experiments did not alter halflives. Simultaneous administration of ASF and BSA-Man did not prolong half lives more than BSA-Man alone with preparation I.
Additional studies performed with preparation III indicated that the effects of BSA-Man on axand 13-phase rate constants of disappearance applied to this preparation as well (table 2) . ax-Phase clearance was prolonged by 76%, whereas a trend toward prolongation of the 13-phase was noted that was not statistically significant. Unfortunately, because our supply of this preparation was limited and exhausted by use in clearance studies and experiments in vitro, it was not possible to directly evaluate effects of ASF on the clearance of preparation III in vivo.
Removal of terminal mannose residues of preparation I by a-mannosidase resulted in a prolongation of ax-phase clearance by an average of 36% (n = 3). Qualitatively similar results were obtained after treatment with Endo-H.
Evaluation of other potential determinants of clearance of t-PA from the circulation. The clearance of t-PA preparation I before and after treatment with plasmin was determined to evaluate the relationship of clearance rates to the proportion of single-and two chain-forms found in each preparation of t-PA. The a-and ,B-phase rate constants of disappearance were unchanged by such treatment despite the complete conversion of t-PA to the two-chain form as documented by SDS-PAGE (data not shown). Active site inhibition with PPACK prolonged the half-time of clearance for both phases and increased the apparent volume of the central compartment by 63% (table 3) . lodination of t-PA I with 125I or with cold iodine (chloramine-T method) led to marked persistence of t-PA in the circulation manifest by prolongation of both a-and 3-phases of clearance as shown in table 3. The specific activity and migration patterns of radioiodinated t-PA on SDS-PAGE were not different from those of untreated t-PA.
Fibrin autography of blood samples obtained se- quentially after intravenous injection of t-PA indicated that circulating t-PA was predominantly in its free form represented by the 55 kilodalton band of fibrinolysis ( figure 5 ). Minimal amounts of high-molecular weight complexes were present at 110 and 170 kilodaltons, which persisted with time. The amount of free t-PA declined with time. The time course of disappearance of free t-PA and high-molecular weight complexes was not altered by administration of BSA-Man (10 mg/kg) in competition experiments.
Discussion
Results from our laboratory and from others have shown that t-PA is an effective thrombolytic agent with a relatively high therapeutic-to-toxic ratio.4 Differences in pharmacokinetic and pharmacodynamic properties of selected preparations of t-PA produced under different conditions have been noted previously in pilot clinical studies. Garabedian et al.'1 observed that the rate of infusion of t-PA necessary to achieve effective coronary thrombolysis with two preparations of t-PA produced under different conditions differed by 25% to 50%. Delineation of factors influencing pharmacologic behavior and affecting clearance of t-PA in vivo is important to design and characterize molecular variants of t-PA with specific biological properties and to develop dose regimens appropriate for specific preparations for clinical use. This study was undertaken to identify biochemical features that affect the pharmacologic properties of t-PA and to elucidate potential biochemical determinants of clearance of t-PA from the circulation.
Characteristic differences in circulating half-lives were seen with three preparations of t-PA expressed from the same cDNA in the same CHO line under disparate conditions of cell culture despite apparent uniformity of the three preparations assessed by molecular weight and specific activity. Isoelectric focusing indicated that the number and pIs of bands with t-PA preparation III differed from those of preparations I and II. These differences may reflect variation in carbohydrate content or less likely limited proteolysis of t-PA during processing.21 Preparations of t-PA and their asialo-derivatives were sialylated with CMP-[14C]
NeuAc with ax-(2,6)-sialyltransferase to identify potential differences in the composition and availability of N-linked oligosaccharides of t-PA for sialylation. Intact t-PA preparation III incorporated almost 10 times more CMP-[14C] NeuAc than preparations I or II indicative of a significant difference in the number of terminal galactose residues available for sialylation. Asialo-derivatives of preparations Land II incorporated sialic acid to the same extent, which was similar to the amount incorporated by intact preparation III, suggesting that these preparations have similar galactose content but differ in content of sialic acid. Thus distinctive biochemical properties reflecting the nature and extent of glycosylation were associated with distinctive biological properties of different preparations of t-PA manifested by characteristic differences in clearance from the circulation. Howevert the biochemical differences observed do not account entirely for the observed differences in clearance as shown by the biochemical uniformity of t-PA preparations I and II despite their differing P-phase rate constants of elimination. Our group and others have shown that clearance of t-PA is mediated primarily by the liver.7 10 Carbohydrate-independent binding and uptake of t-PA have been observed recently in vitro with rat hepatocytes22 and human hepatocytes.* Hepatic receptors that mediate clearance of circulating glycoproteins by recognition of and specific binding of terminal galactose, mannose, N-acetylglucosamine, and fucose moieties of ASN-linked oligosaccharides have been characterized extensively.12'23-25 Mechanisms of clearance of protease-inhibitor complexes have been identified. 26 In the present study, competition by 50-fold molar excesses of BSA-Man and BSA-GlcNAc, neoglycoproteins specific for the Man/GlcNAc receptor, resulted in prolongation of both axand 3-phase rate constants of disposition of preparation 1.27 Enzymatic treatment of preparation I with oa-mannosidase and Endo-H also prolonged clearance. These results suggest that the Conversely, competition with asialofetuin, an asialoglycoprotein specific for the galactose receptor, did not prolong clearance of preparation I, consistent with the findings of Fuchs et al. 30 in mice. The lack of change in clearance after treatment of t-PA with periodate, which destroys terminal galactose residues, is also consistent with this finding.28 These results indicate that the galactose receptor probably does not mediate clearance of t-PA from the circulation. However, as noted previously, it was not possible to directly determine whether or not ASF prolonged the clearance of preparation III, the preparation with terminal galactose residues available for sialylation. Thus interactions with the galactose receptor could occur in t-PA molecules that lack terminal sialic acid residues and contain triantennary oligosaccharides.
Competition with BSA-Man significantly prolonged a-phase clearance oft-PA preparations I and III, as well as (3-phase clearance of preparation I. Because clearance of t-PA remained relatively rapid despite competition with neoglycoproteins, mechanisms besides those dependent on hepatic uptake via specific oligosaccharide receptors must contribute. In a recent abstract, Larsen et al.31 reported that clearance of a variant of t-PA lacking finger and epidermal growth factor domains as well as ASN-linked glycosylation was monoexponential and dramatically prolonged.
Our results indicate that the relative proportion of singleto two-chain t-PA in each preparation was not a major determinant ofclearance in accordance with the observations of others.32 33However, inhibition of the active site oft-PAwith PPACK resulted in prolongation of both phases of clearance and an increase of apparent volume of the central compartment. Some recent reports indicate that active site inhibition does not prolong clearance.30 32However, because I251-labeled t-PA was used in these studies, we evaluated the effect of iodination of t-PA alone on clearance. Prolongation of both phases of clearance with iodination performed with chloramine-T resulted despite preservation of specific enzymatic activity and structural integrity. The alteration of clearance is probably attributable to both an oxidant effect of chloramine-T and an isotope effect judging from the results after iodination with cold sodium iodide. Although our conditions of iodination differed, results indicate that iodination of t-PA with chloramine-T can alter clearance.
Fibrin autography exhibited predominantly free t-PA with minimal concentrations of high-molecular weight complexes during the course ofclearance studies in vivo. The concentrations of complexes of t-PA with protease inhibitors in plasma are dependent on the dose and duration of t-PA infusions and are prominent in patients with infarction given prolonged infusions.15 Inhibitor complexes with t-PA may be cleared through mechanisms different from those of free t-PA as is the case with other serine proteases.2' The appearance of high-molecular weight complexes of t-PA on fibrin autography was not altered by prior administration of BSA-Man. Thus the effect of BSA-Man on clearance is apparently not attributable to differences in the rate or extent of formation of complexes between t-PA and protease inhibitors.
Our results underscore the quantitative dependence of pharmacokinetic properties of t-PA on biochemical characteristics that may not be apparent judging solely by conventional criteria of peptide structure. Glycosylation oft-PA affects clearance, and interactions of t-PA with the Man/GlcNAc-specific glycoprotein receptor via high-mannose type oligosaccharides modifies clearance as well. These observations suggest that modification of biochemical determinants of clearance of t-PA from the circulation can facilitate the development of structural variants with particularly desirable biological properties suitable for specific dose regimens and treatment of diverse clinical conditions with intravenous or alternative routes of administration. 34 
